Skip to main content

Advertisement

Table 3 Primary analysis, baseline covariates after matching, stratified by age

From: Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality

Matching Variable Age < 65 years N = 304 Age ≥ 65 years N = 71 P-value Standardized Mean Difference
TRTa (N, %) 132 (43.4%) 33 (46.5%) 0.738 0.061
Median First Testosterone, ng/dL (IQR) 175 (145, 202) 185 (161, 196) 0.291 0.126
Median Second Testosterone, ng/dL (IQR) 169 (139, 195) 176 (141, 195) 0.526 0.040
Median Income, United States Dollars (IQR) 54,440 (44,810, 71,425) 61,069 (45,653, 66,588) 0.538 0.071
Median Age, years (IQR) 54 (48, 59) 69 (66, 74) < 0.001 0.687
Diabetes (N, %) 116 (38.2%) 39 (54.9%) 0.014 0.341
Tobacco Use (N, %) 2 (0.1%) 0 1 0.115
LDL > 130 mg/dL 37 (12.2%) 1 (1.4%) 0.013 0.438
Median LDL, mg/dL (IQR) 95 (74, 117) 79 (59, 107) 0.001 0.536
Hypertension (N, %) 193 (63.5%) 60 (84.5%) 0.001 0.494
Statin (N, %) 147 (48.4%) 45 (63.4%) 0.032 0.306
BMI ≥ 30 kg/m2 276 (90.8%) 60 (84.5%) 0.179 0.192
Median BMI, kg/m2(IQR) 36.3 (32.2, 41.0) 34.1 (31.1, 37.9) 0.004 0.323
Previous Cardiovascular Disease (N, %) 35 (11.5%) 34 (47.9%) < 0.001 0.868
Charlson Comorbidity Index (N, %)    < 0.001 1.068
0 134 (44.1%) 13 (18.3%)   
1 85 (28.0%) 5 (7.0%)   
> 1 85 (28.0%) 53 (74.6%)   
Composite Outcome (N, %) 15 (4.9%) 13 (18.3%)   
Myocardial Infarction (N, %) 5 (1.6%) 2 (2.8%)   
Stroke (N, %) 8 (2.6%) 8 (11.3%)   
Death (N, %) 2 (0.7%) 3 (4.2%)   
  1. aTRT: Testosterone Replacement Therapy
  2. IQR: Interquartile range
  3. LDL: Low-density lipoproteins
  4. BMI: Body mass index
  5. Patients were matched by age, median income, diabetes, tobacco, hypertension, LDL, stain, aspirin, body mass index (BMI), previous cardiovascular disease (previous acute myocardial infarction or acute cerebrovascular accident, or cerebrovascular or cardiovascular disease), and Charlson Comorbidity Index. Median matched exposure time was 1 month (IQR: 0, 4), max 78 months
  6. A patient treated with TRT with X months of exposure time between baseline and the initiation of treatment was matched to a comparison group patient (no TRT) that had more than X months of follow up since baseline. This period of time (X months) is the matched exposure time